A minimal sequon sufficient for O-linked glycosylation by the versatile oligosaccharyltransferase PglS.

O-glycosylation bioconjugation glycoconjugate vaccine oligosaccharyltransferase sequon

Journal

Glycobiology
ISSN: 1460-2423
Titre abrégé: Glycobiology
Pays: England
ID NLM: 9104124

Informations de publication

Date de publication:
20 09 2021
Historique:
received: 26 03 2021
revised: 29 04 2021
accepted: 07 05 2021
pubmed: 18 5 2021
medline: 1 4 2022
entrez: 17 5 2021
Statut: ppublish

Résumé

Bioconjugate vaccines, consisting of polysaccharides attached to carrier proteins, are enzymatically generated using prokaryotic glycosylation systems in a process termed bioconjugation. Key to bioconjugation are a group of enzymes known as oligosaccharyltransferases (OTases) that transfer polysaccharides to engineered carrier proteins containing conserved amino acid sequences known as sequons. The most recently discovered OTase, PglS, has been shown to have the broadest substrate scope, transferring many different types of bacterial glycans including those with glucose at the reducing end. However, PglS is currently the least understood in terms of the sequon it recognizes. PglS is a pilin-specific O-linking OTase that naturally glycosylates a single protein, ComP. In addition to ComP, we previously demonstrated that an engineered carrier protein containing a large fragment of ComP is also glycosylated by PglS. Here we sought to identify the minimal ComP sequon sufficient for PglS glycosylation. We tested >100 different ComP fragments individually fused to Pseudomonas aeruginosa exotoxin A (EPA), leading to the identification of an 11-amino acid sequence sufficient for robust glycosylation by PglS. We also demonstrate that the placement of the ComP sequon on the carrier protein is critical for stability and subsequent glycosylation. Moreover, we identify novel sites on the surface of EPA that are amenable to ComP sequon insertion and find that Cross-Reactive Material 197 fused to a ComP fragment is also glycosylated. These results represent a significant expansion of the glycoengineering toolbox as well as our understanding of bacterial O-linking sequons.

Identifiants

pubmed: 33997889
pii: 6275361
doi: 10.1093/glycob/cwab043
pmc: PMC8457361
doi:

Substances chimiques

Membrane Proteins 0
Fimbriae Proteins 147680-16-8
Hexosyltransferases EC 2.4.1.-
dolichyl-diphosphooligosaccharide - protein glycotransferase EC 2.4.99.18

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1192-1203

Subventions

Organisme : NIAID NIH HHS
ID : R44 AI131742
Pays : United States
Organisme : NIAID NIH HHS
ID : R44AI131742
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Proc Natl Acad Sci U S A. 2006 May 2;103(18):7088-93
pubmed: 16641107
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5229-34
pubmed: 22431623
Biotechnol Bioeng. 2019 Jun;116(6):1427-1438
pubmed: 30739323
Science. 2002 Nov 29;298(5599):1790-3
pubmed: 12459590
Gene. 1996 Oct 24;177(1-2):133-6
pubmed: 8921858
Glycobiology. 2019 Jul 1;29(7):519-529
pubmed: 30989179
Sci Rep. 2015 Oct 23;5:15573
pubmed: 26493302
Front Microbiol. 2014 Jul 29;5:381
pubmed: 25120536
Lancet Infect Dis. 2017 May;17(5):528-537
pubmed: 28238601
J Infect Dis. 2014 May 15;209(10):1551-61
pubmed: 24308931
Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):14-16
pubmed: 30578318
J Bacteriol. 2007 Nov;189(22):8088-98
pubmed: 17890310
Vaccine. 2014 Mar 14;32(13):1423-30
pubmed: 24492014
Open Biol. 2016 Apr 13;6(4):150243
pubmed: 27110302
Biotechnol J. 2017 Jul;12(7):
pubmed: 28397983
Mol Microbiol. 2015 Jun;96(5):1023-41
pubmed: 25727908
Vaccine. 2016 Jul 29;34(35):4152-4160
pubmed: 27395567
Front Biosci. 2003 May 01;8:s452-71
pubmed: 12700099
Chem Soc Rev. 2018 Dec 10;47(24):9015-9025
pubmed: 30277489
Expert Rev Vaccines. 2020 Jun;19(6):507-527
pubmed: 32627609
Clin Microbiol Rev. 2015 Jul;28(3):871-99
pubmed: 26085553
Mol Microbiol. 1999 Jun;32(5):1022-30
pubmed: 10361304
Vaccine. 2015 Aug 26;33(36):4594-601
pubmed: 26162850
EMBO J. 2006 May 3;25(9):1957-66
pubmed: 16619027
FEMS Microbiol Rev. 2017 Jan;41(1):49-91
pubmed: 27566466
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18655-18663
pubmed: 31455739
J Biol Chem. 2014 Aug 22;289(34):23437-48
pubmed: 24990951
J Biol Chem. 2016 Oct 28;291(44):22924-22935
pubmed: 27634041
mBio. 2016 Apr 26;7(2):e00443-16
pubmed: 27118590
Glycobiology. 2011 Feb;21(2):138-51
pubmed: 20871101
J Biol Chem. 2008 Dec 12;283(50):34596-604
pubmed: 18930921
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3016-21
pubmed: 15703289
Microb Cell Fact. 2010 Aug 11;9:61
pubmed: 20701771
Annu Rev Biochem. 2002;71:635-700
pubmed: 12045108
J Mol Biol. 2001 Dec 7;314(4):823-37
pubmed: 11734000
NPJ Vaccines. 2018 Feb 5;3:4
pubmed: 29423317
PLoS Genet. 2006 Mar;2(3):e31
pubmed: 16532061
Eur J Immunol. 1995 Dec;25(12):3207-14
pubmed: 8566002
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4447-52
pubmed: 19251655
NPJ Vaccines. 2018 Oct 31;3:53
pubmed: 30393571
Vaccine. 2009 Oct 30;27(46):6468-70
pubmed: 19555714
Nat Commun. 2019 Feb 21;10(1):891
pubmed: 30792408
J Biol Chem. 2013 Mar 29;288(13):8849-61
pubmed: 23382388
Nat Rev Microbiol. 2010 Nov;8(11):765-78
pubmed: 20948550

Auteurs

Cory J Knoot (CJ)

VaxNewMo, 4340 Duncan Ave., Suite 202, St. Louis, MO 63110, USA.

Lloyd S Robinson (LS)

VaxNewMo, 4340 Duncan Ave., Suite 202, St. Louis, MO 63110, USA.

Christian M Harding (CM)

VaxNewMo, 4340 Duncan Ave., Suite 202, St. Louis, MO 63110, USA.

Articles similaires

Animals Hemiptera Insect Proteins Phylogeny Insecticides
Humans Stomach Neoplasms Macrophages Tumor Microenvironment Disease Progression
Animals Humans TOR Serine-Threonine Kinases Lupus Erythematosus, Systemic Arthritis, Rheumatoid
Cicer Germination Proteolysis Seeds Plant Proteins

Classifications MeSH